Health CareSnapshot 2026-07-23
Reading ALUR? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. ALUR is currently navigating challenges with its financial performance and management volatility, but it operates in a sector with potential tailwinds that could support future growth.
The market seems to have priced in a cheap valuation compared to peers, indicating that investors may have low expectations for immediate performance. The low fragility tier suggests that the stock is not overly sensitive to sudden changes in market conditions.
Fundamentals are likely to show mixed results as management works on regaining NYSE compliance and pursuing FDA approval for its key product. Recent revenue declines and operating losses indicate ongoing challenges, but there has been some improvement in operating income.
The thesis hinges on the performance of sector bellwethers like UNH, JNJ, and LLY, as their results could influence ALUR's trajectory. Additionally, management's ability to stabilize operations and achieve key milestones will be crucial for future growth.
Over the next 1 to 3 years, ALUR's performance will depend on both sector dynamics and management execution. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Financial results will show if Allurion is getting better. They will also show if it meets rules.
Confirms:Revenue increases from $2.95M in Q1 2026 to above $3.5M in Q2 2026.
Disproves:Revenue declines further below $2.95M in Q2 2026.
Why it matters: Regaining compliance is important. It helps keep the company's public listing and investor trust.
Confirms:The company meets NYSE listing rules and keeps its listing.
Disproves:The company does not meet NYSE listing rules and may be delisted.
Why it matters: This split aims to help regain compliance with NYSE listing standards. Success could improve liquidity and visibility for Allurion.
Confirms:Allurion's stock has traded above $1 on the NYSE for 20 days after the split.
Disproves:Stock price remains below $1 for 20 consecutive trading days after the split.
Why it matters: FDA approval is crucial for Allurion's growth strategy. It could drive revenue and market presence.
Confirms:FDA grants approval for the Allurion Gastric Balloon System.
Disproves:The FDA may deny approval or delay the decision longer than expected.
Why it matters: The CEO leaving could change Allurion's plans and how it grows.
Confirms one read:New CEO appointed with a clear strategy to enhance growth and compliance.
Confirms the other:No new CEO appointed within three months, leading to uncertainty in strategy.
